Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.56 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.56 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.56 |
| ▸ | TLR2 | O60603 | 2/20 | 0.53 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.53 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.44 |
| ▸ | RRM1 | P23921 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22956 | 1.00 | GNAI3 (0.56) | GNAI3GNAO1GNAI1TLR2NOD1 | |
| SCHEMBL10613585 | 1.00 | GNAI3 (0.56) | GNAI3GNAO1GNAI1TLR2NOD1 | |
| SCHEMBL10611658 | 1.00 | GNAI3 (0.56) | GNAI3GNAO1GNAI1TLR2NOD1 | |
| SCHEMBL285284 | 1.00 | GNAI3 (0.56) | GNAI3GNAO1GNAI1TLR2NOD1 | |
| SCHEMBL7771135 | 1.00 | GNAI3 (0.56) | GNAI3GNAO1GNAI1TLR2NOD1 | |
| SCHEMBL10614116 | 1.00 | GNAI3 (0.56) | GNAI3GNAO1GNAI1TLR2NOD1 | |
| SCHEMBL10611883 | 1.00 | GNAI3 (0.56) | GNAI3GNAO1GNAI1TLR2NOD1 | |
| SCHEMBL10609973 | 1.00 | GNAI3 (0.56) | GNAI3GNAO1GNAI1TLR2NOD1 | |
| SCHEMBL10612555 | 1.00 | GNAI3 (0.56) | GNAI3GNAO1GNAI1TLR2NOD1 | |
| SCHEMBL22955 | 1.00 | GNAI3 (0.56) | GNAI3GNAO1GNAI1TLR2NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0162747-B1 | LYSINE ESTERS USED AS ABSORPTION ENHANCING AGENTS | MERCK & CO. INC. (US) | 1988-12-07 | — | — | EP | claimed |
| EP-0162747-A1 | Lysine esters used as absorption enhancing agents | MERCK & CO. INC. (US) | 1985-11-27 | — | — | EP | claimed |
| EP-1073473-B1 | IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2007-10-17 | — | — | EP | disclosed |
| US-20040146462-A1 | Ultrasonic visualisation of perfusion in the myocardium and other tissues is performed using novel gas-containing contrast agent preparations which promote controllable and temporary growth of the gas phase in vivo following administration | GE HEALTHCARE AS (NO) | 2004-07-29 | — | — | US | disclosed |
| EP-1135398-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | Monsanto Technology LLC (US) | 2001-09-26 | — | — | EP | disclosed |
| CN-1306442-A | Improement in or relating to contrast agents | NYCOMED INAGING AS (NO) | 2001-08-01 | — | — | CN | disclosed |
| US-6218563-B1 | Cyanophosphonamides and method for preparation | MONSANTO COMPANY | 2001-04-17 | — | — | US | disclosed |
| EP-1073473-A1 | IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS | Marsden, John Christopher (GB) | 2001-02-07 | — | — | EP | disclosed |
| WO-2000032611-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | MONSANTO TECHNOLOGY LLC (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-1999053963-A1 | IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS | MARSDEN, JOHN, CHRISTOPHER (GB) | 1999-10-28 | — | — | WO | disclosed |
| EP-0162747-B1 | LYSINE ESTERS USED AS ABSORPTION ENHANCING AGENTS | MERCK & CO. INC. (US) | 1988-12-07 | — | — | EP | disclosed |
| US-4749694-A | ENHANCING AGENTS FOR GASTROINTESTINALLY AND RECTALLY ADMINISTEAED DRUGS | MERCK & CO., INC. (US) | 1988-06-07 | — | — | US | disclosed |
| EP-0162747-A1 | Lysine esters used as absorption enhancing agents | MERCK & CO. INC. (US) | 1985-11-27 | — | — | EP | disclosed |
| US-4296095-A | SALTS OF LYSINE ESTERS | BEIERSDORF AKTIENGESELLSCHAFT (DE) | 1981-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040146462-A1 | Ultrasonic visualisation of perfusion in the myocardium and other tissues is performed using novel gas-containing contrast agent preparations which promote controllable and temporary growth of the gas phase in vivo following administration | TNNC1, TNNI3, FABP3 | GNAI3 349/4885GNAO1 576/4885GNAI1 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.